Mindset Pharma Closes Ontario Brain Institute Funding and Announces Private Placement Offering
November 9, 2020
Toronto, Ontario--(Newsfile Corp. - November 9, 2020) - Mindset Pharma Inc. ("Mindset" or the "Company"), a drug discovery and development company focused on developing next generation psychedelic medicines for the treatment of neuropsychiatric and neurological indications with unmet needs, is pleased to announce that it has entered into a secured convertible promissory note transaction with the Ontario Brain Institute ("OBI"). OBI is a provincially funded, not-for-profit organization that accelerates discovery and innovation, benefiting both patients and the economy.
Mindset Pharma Commences In Vivo Program for Its Proprietary Next Generation Psychedelic Drug Candidates and Provides Corporate Update
October 20, 2020
Mindset Pharma Inc. ("Mindset" or the "Company"), a drug discovery and development company at the forefront of the evolving psychedelics space, today announced that it has begun confirmatory in-vivo studies with InterVivo Solutions Inc. ("InterVivo Solutions") to further profile the efficacy, safety and pharmacological properties of Mindset's broad portfolio of patent-pending psychedelic drug candidates.
Mindset Pharma Inc. and North Sur Complete Combination; North Sur Changes Name to Mindset Pharma Inc.
September 15, 2020
Vancouver, British Columbia--(Newsfile Corp. - September 15, 2020) - Mindset Pharma Inc. (formerly, North Sur Resources Inc.) (the "Company") is pleased to announce that it has completed its previously announced business combination with Mindset Pharma Inc. ("Mindset").
Mindset Pharma Announces Promising Test Results of its Novel and Proprietary Psilocybin-Inspired Compounds
August 31, 2020
Mindset Pharma ("Mindset"), a leading drug discovery and development business focused on next-generation psychedelic medicines to treat neuropsychiatric indications with unmet needs, announces today the preliminary screening results of certain patent-pending compounds.
Mindset Pharma Announces Filing of Groundbreaking Psilocybin Synthesis Patent
July 27, 2020
Mindset Pharma (“Mindset”), a leading drug discovery business focused on developing next-generation psychedelic medicines, announces today the filing of a provisional patent application with the USPTO for a groundbreaking process to synthesize psilocybin and psilocin—two of the known active compounds in psychedelic mushrooms.
North Sur Resources and Mindset Pharma Announce Proposed Transaction to Accelerate Development of Medical Psychedelics Industry
June 29, 2020
North Sur Resources Inc. (“North Sur”) and Mindset Pharma Inc. (“Mindset”) are pleased to announce that they have signed a binding letter of intent (the “Letter of Intent”) to combine their corporate entities.
Mindset Pharma Synthesizes Second Generation Medicinal Psychedelic Compounds
May 6, 2020
Mindset Pharma ("Mindset"), a leading drug discovery business focused on developing next-generation psychedelic medicines, announced today that it has successfully synthesized approximately one-quarter of the target compounds identified in its previously filed patent applications
Mindset Pharma Begins Work with Leading R&D Contractor for Next-Generation Psychedelic Drugs
April 14, 2020
Mindset Pharma ("Mindset"), a leading drug discovery business focused exclusively on novel and best in class psychedelics, announced today that preclinical work has begun on the novel psychedelics identified in Mindset's provisional patent applications filed earlier this year.
Mindset Pharma engages InterVivo Solutions for Initial Drug Analysis
February 10, 2020
Mindset Pharma Inc. (“Mindset” or the “Company”) announced today that it has executed a Master Laboratory Services Agreement (the “MLSA”) with InterVivo Solutions Inc. (“InterVivo”). Based in Fergus, Ontario, InterVivo is a specialty preclinical contract research organization which develops and provides translational animal models and transformative research services in an effort to improve the clinical success of new therapeutics, particularly in central nervous system indications.
Mindset Pharma Inc. (“Mindset” or the “Company”) announced today that it has filed a number of provisional patent applications with the USPTO. These patent applications cover a comprehensive range of psychedelic compounds, and their related processing, potential compositions, and therapeutic uses.
Mindset Adds Medicinal Chemist to Scientific Advisory Team
December 1, 2019
Mindset Pharma Inc. (“Mindset” or the “Company”) is pleased to announce that it has engaged Slassi Consulting Services to provide the scientific advisory services of Mr. Malik Slassi on an immediate basis.
Mindset Files Articles of Incorporation and Elects Board of Directors
October 7, 2019
Following months of research and planning, Mindset Pharma Inc. (“Mindset” or the “Company”) has been officially incorporated in Ontario effective today. Mindset’s is a psychedelic-based drug discovery business incorporated for the purpose of creating novel and patentable psychedelic compounds for the treatment of neurological and psychiatric disorders.